"It was a pleasure presenting at the Bioconjugates conference in June 2014. The presentations and discussion were very stimulating and there was excellent new information."- Philip Howard, Ph.D., Chief Scientific Officer, Spirogen, United Kingdom
"Great variety of bioconjugation modalities. I'm sure this sort of crosstalk will create new innovations."- Roger Pak, Pfizer
"A great conference with all the experienced scientists involved in ADC therapeutics - 'one-and-only shop for ADCs' - great location too."- Ananda Senevir, Agensys
Special Discounted Hotel Rate Available Until May 13, 2014 by 5pm. To book your room, call (888) 421-1442 and mention that you are an IBC attendee at this event.
From developing the platforms to create next generation ADCs to the evolution of nanoparticle conjugates, the bioconjugations landscape is rapidly evolving. IBC's 3 annual conference will bring together industry leaders and world-renowned academics, to provide you the latest updates on key topics including novel payloads, next generation ADCs and advances in the development lifecycle to allow you to improve your manufacturability and propel your therapeutic candidate toward commercial success.
Topics to be covered in 2015 include:
Novel Payload and Binding Techniques
Site-Specific Conjugation Methods and Strategies
Beyond ADCs - Assessing Other Areas for Breakthroughs in Bioconjugates
Together these 3 events give you access to this unique forum for the cross-fertilization of ideas to overcome your greatest challenges, from reducing risks to managing costs to expediting tight timelines, and, ultimately, propelling these promising candidates toward commercial success.